Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Regulatory News (OVB)

  • There is currently no data for OVB

Further re Norplat Ltd

12 May 2005 13:20

Ovoca Resources PLC12 May 2005 NEWS RELEASE May 12, 2005 Ovoca Resource plc ('Ovoca' or the 'Company') Further Information on Norplat Limited ('Norplat') Following the acquisition of a 78 percent interest in Norplat Limited thedirectors of Ovoca Resources plc (OVG.I Dublin and OVG.L London) wish toprovide further information on the exploration assets the Company has acquired. Norplat Limited is a private exploration company created six years ago by formerOxus Gold Plc Managing Directors for the purposes of exploiting the mineralpotential of the Russian Federation, in particular focussing on platinum andgold deposits in northwest Russia. The directors of Norplat, supported by ateam of local and western geological professionals, have between them over 95years of experience in developing mineral properties in the Former Soviet Union. Norplat owns a 95 percent equity interest in its Russian subsidiary "Black FoxResources AOA " which currently holds the 152 square kilometre Kolmozero-Voronyaexploration license in the Kola Peninsula of northwest Russia near the Finnishborder. The license encompasses a number of mineral prospects which includeplatinum, gold, copper, molybdenum, nickel and rare earth minerals. Two exploration prospects, Oleninskoye and Nyalm, have already been drilled andtrenched with combined resources of 900,000 ounces of gold so far outlined inthe P1 category based on the Russian resource classification methodology. The2005 trenching and a 7,000 metre diamond drilling programme has alreadycommenced on both prospects. This follows on from the results of last year'sdrilling programme and assay results are expected in the coming weeks. At Oleninskoye, the more advanced prospect, the 2004 and previous drillingprogrammes have indicated that gold mineralisation occurs in quartz lenses ofthickness ranging from 2 to 5 metres with an average strike length of 85 metresand an overall strike length of 5 kilometers for all six mineralised zones.Drill intersections indicated that the gold mineralisation extends to depths inexcess of 100 metres and is open both along strike and in depth. A recentresource estimate calculated by Norplat based on drilling on Vein 3 has outlined1,020,000 tonnes at an average grade of 13.9 grammes per tonne and a goldequivalent of 455,000 ounces. In addition to this gold mineralisation, recentdrilling has intersected spatially related platinum mineralisation within themetabasalt and metadiabase host rocks of the gold bearing quartz veins andstockworks with platinum grades of up to 3.2 grammes per tonne over thicknessesof over 10 metres. It is believed that these host rocks are extensive throughoutthe license and assays from reject samples from previous gold exploration,before Norplat's ownership of the licence, indicate the presence of platinum inother gold prospects where assays for platinum were not run. The acquisition of a 78 percent shareholding in Norplat, with a call option toacquire the remaining Norplat issued shares and warrants, has not onlydramatically increased the resource base of Ovoca but has brought onboard adynamic experienced technical management team to advance not only the Kolaprojects but also the licenses in Sweden and Ireland. Further information will be provided on the results of the 2005 drillingprogramme and prospects for all of the Company's exploration prospects in duecourse. Contacts Barrie Oakes +44 (0)7951139266 Roger Turner +44 (0)773092813 John O'Connor +353 (0)1 491 2944 Richard O'Shea +353 (0)87 2560397 John Frain (Davy Corporate Finance) +353 (0)1 679 6363 This announcement has been issued through the Companies Announcement Service of the Irish Stock Exchange. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Jul 20227:00 amRNSCompletion of Enrollment in Phase II Study
30th Jun 20227:00 amRNSAnnual Financial Report
7th Mar 20229:00 amRNSStatement re Russian Business Operations
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
22nd Feb 20223:30 pmRNSRussian Marketing Authorisation for Orenetide
31st Jan 20227:00 amRNSBoard Changes and Update
30th Dec 20217:00 amRNSDirectorate Change
4th Nov 20213:53 pmRNSHolding(s) in Company
4th Nov 20213:50 pmRNSDirector/PDMR Shareholding
4th Nov 20213:46 pmRNSBoard Change
14th Sep 20217:00 amRNSInterim Results
29th Jul 20215:00 pmRNSResult of AGM
24th Jun 20217:00 amRNSAnnual Report and Notice of AGM
10th Mar 20217:00 amRNSMigration of Participating Securities
16th Feb 20212:00 pmRNSResult of EGM
29th Jan 20217:00 amRNSFirst Patient Enrolled in Phase II Study - BP-101
25th Jan 20213:30 pmRNSNotice of EGM
5th Jan 20217:00 amRNSRe-Filing of Marketing Authorisation Application
17th Dec 20202:45 pmRNSResult of AGM
27th Nov 20203:08 pmRNSNotice of AGM
9th Oct 20207:00 amRNSAppointment of Chief Business Officer
2nd Oct 202011:06 amRNSSecond Price Monitoring Extn
2nd Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 20209:05 amRNSSecond Price Monitoring Extn
2nd Oct 20209:00 amRNSPrice Monitoring Extension
2nd Oct 20207:00 amRNSUpdate re Russian Marketing Authorisation
28th Sep 20207:00 amRNSDeath of a Director
21st Sep 20207:00 amRNSInterim Results
14th Aug 202011:05 amRNSSecond Price Monitoring Extn
14th Aug 202011:00 amRNSPrice Monitoring Extension
26th Jun 20207:00 amRNSAnnual Report
14th Apr 20202:05 pmRNSSecond Price Monitoring Extn
14th Apr 20202:00 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSAcquisition of Remaining Minority Interest in IVIX
7th Nov 201912:45 pmRNSAttendance at Bio-Europe Conference
16th Sep 20197:00 amRNSInterim Results
12th Sep 20197:00 amRNSFiling of Marketing Authorisation Application
28th Aug 20197:00 amRNSDirectorate Change
8th Aug 20194:14 pmRNSResult of AGM
8th Aug 20199:05 amRNSSecond Price Monitoring Extn
8th Aug 20199:00 amRNSPrice Monitoring Extension
8th Aug 20197:00 amRNSAGM Statement
26th Jul 20197:00 amRNSDirectorate Change
25th Jul 20194:41 pmRNSSecond Price Monitoring Extn
25th Jul 20194:35 pmRNSPrice Monitoring Extension
28th Jun 20197:00 amRNSAnnual Report and Notice of AGM
23rd Apr 20197:00 amRNSUS and EU Clinical Development Plans
29th Mar 20197:00 amRNSDirector/PDMR Shareholding
27th Mar 20197:00 amRNSOperational Update & Additional Investment in IVIX

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.